pharma · Syphilis · Human Immunodeficiency Virus
MEDA Pharma GmbH
MEDA Pharma GmbH & Co. KG
MEDA Pharma GmbH is a pharma organization headquartered in CN. Primary therapeutic focus areas include Syphilis, Human Immunodeficiency Virus, Non Alcoholic Fatty Liver Disease, Human immunodeficency virus, COVID-10 infe
Bad Homburg, DE HQ
89 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Bad Homburg, DE
- Employees
- 89
- Programs
- 8
- Drugs
- 28
- Patents
- 0
BCN05-Bari
Phase 2 · small molecule · Human immunodeficency virus
BCN05-Bari for Human immunodeficency virus is a Phase 2 program (small_molecule) at MEDA Pharma GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Internal code BCN05-Bari
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- MEDA Pharma GmbH & Co. KG
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Human immunodeficency virus
- Status
- active
- Trials
- 1